MA25501A1 - Traitement de l'endometriosis ou de la sterilite ou amelioration de la fertilite. - Google Patents

Traitement de l'endometriosis ou de la sterilite ou amelioration de la fertilite.

Info

Publication number
MA25501A1
MA25501A1 MA26584A MA26584A MA25501A1 MA 25501 A1 MA25501 A1 MA 25501A1 MA 26584 A MA26584 A MA 26584A MA 26584 A MA26584 A MA 26584A MA 25501 A1 MA25501 A1 MA 25501A1
Authority
MA
Morocco
Prior art keywords
endometriosis
fertility
sterility
improvement
treatment
Prior art date
Application number
MA26584A
Other languages
English (en)
Inventor
William J Bologna
Howard L Levine
Dominique De Ziegler
Original Assignee
Columbia Lab Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia Lab Bermuda Ltd filed Critical Columbia Lab Bermuda Ltd
Publication of MA25501A1 publication Critical patent/MA25501A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
MA26584A 1999-10-05 2002-04-04 Traitement de l'endometriosis ou de la sterilite ou amelioration de la fertilite. MA25501A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15775499P 1999-10-05 1999-10-05
US66838400A 2000-09-25 2000-09-25

Publications (1)

Publication Number Publication Date
MA25501A1 true MA25501A1 (fr) 2002-07-01

Family

ID=26854456

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26584A MA25501A1 (fr) 1999-10-05 2002-04-04 Traitement de l'endometriosis ou de la sterilite ou amelioration de la fertilite.

Country Status (28)

Country Link
EP (1) EP1220667B1 (fr)
JP (2) JP2003510354A (fr)
KR (1) KR100738724B1 (fr)
CN (1) CN1218694C (fr)
AR (1) AR028487A1 (fr)
AT (1) ATE271860T1 (fr)
AU (1) AU780736B2 (fr)
BR (1) BR0014548A (fr)
CA (1) CA2385974C (fr)
CO (1) CO5251423A1 (fr)
DE (1) DE60012554T2 (fr)
DK (1) DK1220667T3 (fr)
ES (1) ES2223581T3 (fr)
GE (1) GEP20043313B (fr)
HK (1) HK1044120B (fr)
HU (1) HU225990B1 (fr)
IL (2) IL148784A0 (fr)
MA (1) MA25501A1 (fr)
MX (1) MXPA02003453A (fr)
MY (1) MY129518A (fr)
NO (1) NO329663B1 (fr)
NZ (1) NZ518429A (fr)
PE (1) PE20010742A1 (fr)
PT (1) PT1220667E (fr)
TR (1) TR200200899T2 (fr)
TW (1) TWI280877B (fr)
UA (1) UA74168C2 (fr)
WO (1) WO2001024788A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101327326A (zh) * 2001-10-29 2008-12-24 哥伦比亚实验室(百慕大群岛)有限公司 阴道给药治疗骨盆痛和不孕症的抗节律障碍剂
US8425892B2 (en) 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
ES2237298B1 (es) 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
EP1872775A1 (fr) 2006-06-29 2008-01-02 Polichem S.A. Emploi d'une matrice hydrophile contenant un dérivé polyacrylique, un éther de cellulose et un désintégrant, pour la production d'un médicament pour le traitement des troubles génitales d'une femme
ES2344673B1 (es) 2008-08-07 2011-05-03 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral.
ES2344675B1 (es) 2008-12-19 2011-04-28 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
KR102166867B1 (ko) * 2010-03-22 2020-10-19 앨러간 파마슈티컬스 인터내셔널 리미티드 항프로게스틴의 비독성 전달을 위한 조성물들과 그 방법들
KR101010031B1 (ko) * 2010-12-08 2011-01-21 류상범 흡수식 냉온수기용 엘리미네이터
WO2013181449A1 (fr) 2012-05-31 2013-12-05 Repros Therapeutics Inc. Formulations et méthodes d'administration vaginale d'antiprogestines
WO2014070517A1 (fr) 2012-11-02 2014-05-08 Repros Therapeutics Inc. Méthodes et compositions de traitement d'affections dépendant de la progestérone

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241087A (en) * 1979-04-02 1980-12-23 William H. Rorer, Inc. Dysmenorrhea treatment
IL93661A0 (en) * 1989-03-07 1990-12-23 Adeza Biomedical Corp Endometriosis diagnosis and kits and reagents therefor
JP2602456B2 (ja) * 1990-04-12 1997-04-23 雪印乳業株式会社 子宮内膜症治療剤
IT1251114B (it) * 1991-07-26 1995-05-04 Farcon Ag Forme farmaceutiche antivirali per applicazione vaginale
DE69819748T2 (de) * 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen

Also Published As

Publication number Publication date
DK1220667T3 (da) 2004-12-06
BR0014548A (pt) 2002-06-04
ES2223581T3 (es) 2005-03-01
UA74168C2 (uk) 2005-11-15
MXPA02003453A (es) 2002-08-20
NO20021591D0 (no) 2002-04-04
NZ518429A (en) 2004-02-27
WO2001024788A2 (fr) 2001-04-12
CN1377264A (zh) 2002-10-30
MY129518A (en) 2007-04-30
CO5251423A1 (es) 2003-02-28
IL148784A0 (en) 2002-09-12
KR100738724B1 (ko) 2007-07-12
KR20020062285A (ko) 2002-07-25
ATE271860T1 (de) 2004-08-15
CN1218694C (zh) 2005-09-14
TWI280877B (en) 2007-05-11
JP2010018639A (ja) 2010-01-28
EP1220667A2 (fr) 2002-07-10
AU780736B2 (en) 2005-04-14
AU7525000A (en) 2001-05-10
HUP0203050A2 (hu) 2003-02-28
HU225990B1 (en) 2008-02-28
WO2001024788A3 (fr) 2001-12-06
HUP0203050A3 (en) 2006-02-28
GEP20043313B (en) 2004-03-10
DE60012554D1 (de) 2004-09-02
CA2385974C (fr) 2010-01-26
NO329663B1 (no) 2010-11-29
PE20010742A1 (es) 2001-07-19
CA2385974A1 (fr) 2001-04-12
AR028487A1 (es) 2003-05-14
DE60012554T2 (de) 2005-11-24
HK1044120B (zh) 2004-12-17
HK1044120A1 (en) 2002-10-11
EP1220667B1 (fr) 2004-07-28
PT1220667E (pt) 2004-11-30
JP2003510354A (ja) 2003-03-18
NO20021591L (no) 2002-05-28
IL148784A (en) 2006-12-31
TR200200899T2 (tr) 2002-07-22

Similar Documents

Publication Publication Date Title
CY2018020I1 (el) Θεραπεια της νοσου ρομρε
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
PT1233973E (pt) Derivados de adenosina n6-heterociclicos 5'-tio-substituida agonistas parciais ou totais de a1
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
DZ1877A1 (fr) Forme posologiques d'azithromycine pour le traitement d'infection microbiennes.
MA26207A1 (fr) Compositions de traitement de l'eau.
DE60023043T2 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
DZ2396A1 (fr) Traitement de l'eau
DZ3167A1 (fr) Combinaison de bactéries d'acide lactique et son utilisation pour prevenir et/ou traiter les infections et les états inflammatoires.
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
MA25411A1 (fr) Microorganismes attenues pour le traitement d'infection.
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
ES2191075T3 (es) 8-arilalquil- y 8-arilheteroalquil-5,11-dihidro-6h-dipirido-(3,2-b:2',3'-e)(1,4)diazepinas y su uso en la prevencion o tratamiento de infecciones por hiv.
MA25501A1 (fr) Traitement de l'endometriosis ou de la sterilite ou amelioration de la fertilite.
DE69711649T2 (de) P1, p4-dithio-p2,p3-monochloromethylen 5',5'''-diadenosin-p1,p4-tetraphosphat verwendet als anti-thrombose mittel
MA26896A1 (fr) Utilisation de compositions d'antibiotiques azalides pour le traitement ou la prevention d'une infection par des bacteries ou protozoaires chez des mammiferes
MA26289A1 (fr) Faible concentration de peroxyde pour le traitement ou la prevention d'infections vaginales
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
BR0012921A (pt) Compostos calcilìticos
DZ1988A1 (fr) Thérapie de combinaison pour le traitement de l'hiv.
MY124071A (en) Treatment of viral disease in swine
DZ3320A1 (fr) Complexe comprenant de l'eletriptane et de la sulphobutylether-cyclodextrine pour le traitement de la migraine
NO20012541D0 (no) Anvendelse av fosfonomaursyrederivater for behandling av infeksjoner
FR2698102B1 (fr) Composition destinée au lavage de la peau ou des muqueuses.
NO20022949D0 (no) Attenuerte mikroorganismer for behandling av infeksjon